Literature DB >> 19879957

Synthetic therapeutic peptides: science and market.

Patrick Vlieghe1, Vincent Lisowski, Jean Martinez, Michel Khrestchatisky.   

Abstract

The decreasing number of approved drugs produced by the pharmaceutical industry, which has been accompanied by increasing expenses for R&D, demands alternative approaches to increase pharmaceutical R&D productivity. This situation has contributed to a revival of interest in peptides as potential drug candidates. New synthetic strategies for limiting metabolism and alternative routes of administration have emerged in recent years and resulted in a large number of peptide-based drugs that are now being marketed. This review reports on the unexpected and considerable number of peptides that are currently available as drugs and the chemical strategies that were used to bring them into the market. As demonstrated here, peptide-based drug discovery could be a serious option for addressing new therapeutic challenges. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879957     DOI: 10.1016/j.drudis.2009.10.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  340 in total

1.  Generating orally active galanin analogues with analgesic activities.

Authors:  Charles R Robertson; Timothy H Pruess; Erin Grussendorf; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2012-02-28       Impact factor: 3.466

2.  Identification of novel specific allosteric modulators of the glycine receptor using phage display.

Authors:  Megan E Tipps; Jessica E Lawshe; Andrew D Ellington; S John Mihic
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

3.  Fashioning drugs for stroke.

Authors:  Ted Weita Lai; Yu Tian Wang
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

4.  Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.

Authors:  Veronika Mäde; Kathrin Bellmann-Sickert; Anette Kaiser; Jens Meiler; Annette G Beck-Sickinger
Journal:  ChemMedChem       Date:  2014-08-22       Impact factor: 3.466

5.  An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model.

Authors:  Tetsuya Nishimoto; Logan Mlakar; Takahisa Takihara; Carol Feghali-Bostwick
Journal:  Int Immunopharmacol       Date:  2015-08-24       Impact factor: 4.932

Review 6.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

8.  Template-constrained macrocyclic peptides prepared from native, unprotected precursors.

Authors:  Kenneth V Lawson; Tristan E Rose; Patrick G Harran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

Review 9.  Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review.

Authors:  Arrigo F G Cicero; Federica Fogacci; Alessandro Colletti
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

10.  Hollow Microparticles as a Superior Delivery System over Solid Microparticles for the Encapsulation of Peptides.

Authors:  Sharad Kharel; Archana Gautam; Andreas Dickescheid; Say Chye Joachim Loo
Journal:  Pharm Res       Date:  2018-08-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.